descriptionPublicationkeyboard_double_arrow_right Other literature type , Article 2021 Portugal, France, Lithuania, Belgium, Italy, Italy, Belgium, Spain, United States MDPI AG EC | PRIME, EC | Eat2beNICE
Isabel Baenas; Mikel Etxandi; Lucero Munguía; Roser Granero; Gemma Mestre-Bach; Isabel Sánchez; Emilio Ortega; Alba Andreu; Violeta L. Moize; Jose-Manuel Fernández-Real; Francisco J. Tinahones; Carlos Diéguez; Gema Frühbeck; Daniel Le Grange; Kate Tchanturia; Andreas Karwautz; Michael Zeiler; Hartmut Imgart; Annika Zanko; Angela Favaro; Laurence Claes; Ia Shekriladze; Eduardo Serrano-Troncoso; Raquel Cecilia-Costa; Teresa Rangil; Maria Eulalia Loran-Meler; José Soriano-Pacheco; Mar Carceller-Sindreu; Rosa Navarrete; Meritxell Lozano; Raquel Linares; Carlota Gudiol; Jordi Carratala; Maria T. Plana; Montserrat Graell; David González-Parra; José A. Gómez-del Barrio; Ana R. Sepúlveda; Jéssica Sánchez-González; Paulo P. P. Machado; Anders Håkansson; Ferenc Túry; Bea Pászthy; Daniel Stein; Hana Papezová; Jana Gricova; Brigita Bax; Mikhail F. Borisenkov; Sergey V. Popov; Denis G. Gubin; Ivan M. Petrov; Dilara Isakova; Svetlana V. Mustafina; Youl-Ri Kim; Michiko Nakazato; Nathalie Godart; Robert van Voren; Tetiana Ilnytska; Jue Chen; Katie Rowlands; Ulrich Voderholzer; Alessio M. Monteleone; Janet Treasure; Susana Jiménez-Murcia; Fernando Fernández-Aranda;
Background. The COVID-19 lockdown has had a significant impact on mental health. Patients with eating disorders (ED) have been particularly vulnerable. Aims. (1) To explore changes in eating-related symptoms and general psychopathology during lockdown in patients with an ED from various European and Asian countries; and (2) to assess differences related to diagnostic ED subtypes, age, and geography. Methods. The sample comprised 829 participants, diagnosed with an ED according to DSM-5 criteria from specialized ED units in Europe and Asia. Participants were assessed using the COVID-19 Isolation Scale (CIES). Results. Patients with binge eating disorder (BED) experienced the highest impact on weight and ED symptoms in comparison with other ED subtypes during lockdown, whereas individuals with other specified feeding and eating disorders (OFSED) had greater deterioration in general psychological functioning than subjects with other ED subtypes. Finally, Asian and younger individuals appeared to be more resilient. Conclusions. The psychopathological changes in ED patients during the COVID-19 lockdown varied by cultural context and individual variation in age and ED diagnosis. Clinical services may need to target preventive measures and adapt therapeutic approaches for the most vulnerable patients. We thank CERCA Programme/Generalitat de Catalunya for institutional support. This manuscript and research was supported by grants from the Department of Health of the Generalitat de Catalunya by the call Pla estratègic de recerca i innovació en salut (PERIS, SLT006/17/00077), the Ministerio de Economía y Competitividad (PSI201568701R), Fondo de Investigación Sanitario (FIS) (INT19/00046, PI17/01167, PI20/132), CIBERINFEC (CB21/13/00009) and co-funded by FEDER funds /European Regional Development Fund (ERDF), a way to build Europe (Eat2beNICE/ H2020-SFS-2016-2; Ref 728018; and PRIME/ H2020-SC1-BHC-2018-2020; Ref: 847879). CIBEROBN, CIBERSAM, CIBERINFEC and CIBERDEM are all initiatives of Instituto de Salud Carlos III (ISCIII). GMB is supported by a postdoctoral grant from FUNCIVA. PPM was supported, in part, by a Portuguese Foundation for Science and Technology grant (POCI-01-0145-FEDER-028145). IB was partially supported by a Post-Residency Grant from the Research Committee of the University Hospital of Bellvitge (HUB; Barcelona, Spain) 2020–2021. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Fondo Investigacion Sanitario-FIS, Grant/Award Numbers: FIS, INT19/00046, PI17/01167; Ministerio de Economia y Competitividad, Grant/Award Number: PSI2015-68701-R; Portuguese Foundation for Science and Technology grant, Grant/Award Number: POCI-01-0145-FEDER-028145; Consejo Nacional de Ciencia y Tecnologia; Generalitat de Catalunya; European Regional Development Fund. Data Availability Statement: Individuals may inquire with Fernández-Aranda regarding availability of the data as there is ongoing studies using the data. To avoid overlapping research efforts, Fernández-Aranda will consider a request on a case-by-case basis.
Infectious disease; Influenza; Vaccine safety Enfermedad infecciosa; Gripe; Seguridad de las vacunas Malaltia infecciosa; Grip; Seguretat de les vacunes Introduction Seasonal influenza poses a major public health burden worldwide. Influenza vaccines, updated yearly to match circulating strains based on World Health Organization (WHO) recommendations, are the cornerstone of prevention and require regular monitoring. The COVID-19 pandemic is expected to cause logistical, site access and medical staff constraints and could affect the safety profile of influenza vaccines. Methods Following European Medicines Agency guidance, an enhanced safety surveillance (ESS) study assessed the frequency and severity of predefined and other adverse events (AEs) occurring within 7 days of receiving GSK’s inactivated quadrivalent seasonal influenza vaccine (IIV4), in Belgium, Germany and Spain in 2020/21, using adverse drug reaction (ADR) cards. Results During the 2020/21 influenza season, 1054 participants vaccinated with GSK’s IIV4 were enrolled (all adults in Belgium and Germany, 30% adults/70% children in Spain); 96 eligible children received a second dose. Overall, 1042 participants completed the study. After doses 1 and 2, 98.9% and 100% of participants, respectively, returned their completed ADR card. After doses 1 and 2, 37.8% (398/1054) and 13.5% (13/96) of participants, respectively, reported at least one AE. The most frequently reported categories of AEs were “general disorders and administration site conditions” (e.g. injection site pain) and “nervous system disorders” (e.g. headache). There were no deaths or serious AEs deemed related to GSK’s IIV4. Conclusion This ESS study assessed AEs in near real time. The COVID-19 pandemic did not alter the safety profile of GSK’s IIV4. No safety signals were detected during the study, which confirms the excellent safety profile of GSK’s IIV4. GlaxoSmithKline Biologicals SA funded this study (study number 207750) and was involved in all stages of the study, including analysis of the data. GlaxoSmithKline Biologicals SA also took charge of all costs associated with the development and publication of this present manuscript, including the Journal’s Rapid Service Fee.
Respiratory infections and tuberculosis Infecciones respiratorias y tuberculosis Infeccions respiratòries i tuberculosi Due to the large number of patients with severe coronavirus disease 2019 (COVID-19), many were treated outside the traditional walls of the intensive care unit (ICU), and in many cases, by personnel who were not trained in critical care. The clinical characteristics and the relative impact of caring for severe COVID-19 patients outside the ICU is unknown. This was a multinational, multicentre, prospective cohort study embedded in the International Severe Acute Respiratory and Emerging Infection Consortium World Health Organization COVID-19 platform. Severe COVID-19 patients were identified as those admitted to an ICU and/or those treated with one of the following treatments: invasive or noninvasive mechanical ventilation, high-flow nasal cannula, inotropes or vasopressors. A logistic generalised additive model was used to compare clinical outcomes among patients admitted or not to the ICU. A total of 40 440 patients from 43 countries and six continents were included in this analysis. Severe COVID-19 patients were frequently male (62.9%), older adults (median (interquartile range (IQR), 67 (55–78) years), and with at least one comorbidity (63.2%). The overall median (IQR) length of hospital stay was 10 (5–19) days and was longer in patients admitted to an ICU than in those who were cared for outside the ICU (12 (6–23) days versus 8 (4–15) days, p<0.0001). The 28-day fatality ratio was lower in ICU-admitted patients (30.7% (5797 out of 18 831) versus 39.0% (7532 out of 19 295), p<0.0001). Patients admitted to an ICU had a significantly lower probability of death than those who were not (adjusted OR 0.70, 95% CI 0.65–0.75; p<0.0001). Patients with severe COVID-19 admitted to an ICU had significantly lower 28-day fatality ratio than those cared for outside an ICU. This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome (215091/Z/18/Z), the Bill and Melinda Gates Foundation (OPP1209135), Canadian Institutes of Health Research Coronavirus Rapid Research Funding Opportunity OV2170359, grants from Rapid European COVID-19 Emergency Response Research (Horizon 2020 project 101003589), the European Clinical Research Alliance on Infectious Diseases (965313), The Imperial National Institute for Health Research (NIHR) Biomedical Research Centre, and The Cambridge NIHR Biomedical Research Centre; and endorsed by the Irish Critical Care Clinical Trials Group, co-ordinated in Ireland by the Irish Critical Care Clinical Trials Network at University College Dublin and funded by the Health Research Board of Ireland (CTN-2014-12). Data and Material provision was supported by grants from: the NIHR (award CO-CIN-01), the Medical Research Council (grant MC_PC_19059), the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) (award 200907), Wellcome Trust (Turtle, Lance-fellowship 205228/Z/16/Z), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award IS-BRC-1215-20013), and NIHR Clinical Research Network providing infrastructure support. This work was by Research Council of Norway grant number 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner.
descriptionPublicationkeyboard_double_arrow_right Article 2021 Netherlands, Belgium, Belgium, Belgium, Italy American Society of Clinical Oncology (ASCO)
Authors: Concetta Elisa Onesti; Marco Tagliamento; Giuseppe Curigliano; Nadia Harbeck; +16 Authors
Concetta Elisa Onesti; Marco Tagliamento; Giuseppe Curigliano; Nadia Harbeck; Rupert Bartsch; Hans Wildiers; Vivianne C. G. Tjan-Heijnen; Miguel Martin; Sylvie Rottey; Daniele Generali; Mario Campone; Massimo Cristofanilli; Lajos Pusztai; Marc Peeters; Guy Berchem; Javier Cortes; Thomas Ruhstaller; Eva Ciruelos; Hope S. Rugo; Guy Jerusalem;
PURPOSEThe COVID-19 pandemic has affected healthcare systems globally, leading to reorganization of medical activities. We performed an international survey aimed to investigate the medium- and long-term impact on oncology units.MATERIALS AND METHODSAn 82-item survey was distributed from June 17 to July 14, 2020 among medical oncologists worldwide.RESULTSOne hundred nine medical oncologists from 18 countries in Europe (n = 93), United States (n = 5), and Latin America (n = 11) answered the survey. A systematic tracing of COVID-19–positive patients was continued in the postacute phase by 77.1% of the centers; 64.2% of the respondents participated in a local registry and 56% in international or national registries of infected patients. Treatment adaptations were introduced, and surgery was the most affected modality being delayed or canceled in more than 10% of patients in 34% of the centers, whereas early cessation of palliative treatment was reported in 32.1% of the centers; 64.2% of respondents reported paying attention to avoid undertreatments. The use of telemedicine has been largely increased. Similarly, virtual tools are increasingly used particularly for medical education and international or national or multidisciplinary meetings. 60.6% of the participants reduced clinical activity, and 28.4% compensated by increasing their research activity. Significant reduction of clinical trial activities is expected in 37% of centers this year. The well-being of healthcare staff would not recover by the end of the year according to 18% of the participants.CONCLUSIONThe COVID-19 outbreak has had a major impact on oncologic activity, which will persist in the future, irrespective of geographical areas.
descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 2021 United Kingdom, Belgium, Turkey Ovid Technologies (Wolters Kluwer Health) NHMRC | Precision treatment for m..., NHMRC | Precision therapy for neu...
NHMRC| Precision treatment for multiple sclerosis: Maximising the effect of immunomodulatory therapy ,
NHMRC| Precision therapy for neurological diseases
Authors: Steve Simpson-Yap; Edward De Brouwer; Tomas Kalincik; Nick Rijke; +43 Authors
Steve Simpson-Yap; Edward De Brouwer; Tomas Kalincik; Nick Rijke; J. Hillert; Clare Walton; Gilles Edan; Yves Moreau; Tim Spelman; Lotte Geys; Tina Parciak; Clément Gautrais; Nikola Lazovski; Ashkan Pirmani; Amin Ardeshirdavanai; Lars Forsberg; Anna Glaser; Robert N. McBurney; Hollie Schmidt; Arnfin Bergmann; Stefan Braune; Alexander Stahmann; Rodden M. Middleton; Amber Salter; Robert J. Fox; Anneke Van Der Walt; Helmut Butzkueven; Raed Alroughani; Serkan Ozakbas; Juan Ignacio Rojas; Ingrid van der Mei; Nupur Nag; Rumen Ivanov; Guilherme Sciascia do Olival; Alice Estavo Dias; Melinda Magyari; Doralina Guimarães Brum; Maria Fernanda Mendes; Ricardo Alonso; Richard S. Nicholas; Johana Bauer; Anibal Chertcoff; Anna Zabalza; Georgina Arrambide; Alexander Fidao; Giancarlo Comi; Liesbet M. Peeters;
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosi múltiple Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosis múltiple Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Multiple Sclerosis Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01–2.41; aOR 2.43, 95% CI 1.48–4.02) and ICU admission (aOR 2.30, 95% CI 0.98–5.39; aOR 3.93, 95% CI 1.56–9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54–10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29–2.38; aOR 2.76, 95% CI 1.87–4.07) and ICU admission (aOR 2.55, 95% CI 1.49–4.36; aOR 4.32, 95% CI 2.27–8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09–12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13–3.07; aOR 2.88, 95% CI 1.68–4.92) and ICU admission (aOR 2.13, 95% CI 0.85–5.35; aOR 3.23, 95% CI 1.17–8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71–17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. The operational costs linked to this study are funded by the Multiple Sclerosis International Federation (MSIF) and the Multiple Sclerosis Data Alliance (MSDA), acting under the umbrella of the European Charcot Foundation. The MSDA receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Canopy Growth Corp, Genzyme, Icometrix, Merck, Mylan, Novartis, QMENTA, Quanterix, and Roche. MSIF receives income from a range of corporate sponsors, recently including Biogen, Bristol-Myers Squibb (formerly Celgene), Genzyme, Med-Day, Merck, Mylan, Novartis, and Roche. This work was supported by the Flemish government under the Onderzoeksprogramma Artificiële Intelligentie Vlaanderen programme and the Research Foundation Fladers (FWO) for ELIXIR Belgium–Flanders (FWO) for ELIXIR Belgium. The central platform was provided by QMENTA, and the computational resources used in this work were provided by Amazon. The statistical analysis was carried out at CORe, The University of Melbourne, with support from the National Health and Medical Research Council (NHMRC; 1129189 and 1140766).
descriptionPublicationkeyboard_double_arrow_right Article 2021 Belgium, Italy, Netherlands Springer Science and Business Media LLC
Authors: Anne M. Spanjaart; Per Ljungman; Rafael de la Cámara; Gloria Tridello; +30 Authors
Anne M. Spanjaart; Per Ljungman; Rafael de la Cámara; Gloria Tridello; Valentín Ortiz-Maldonado; Alvaro Urbano-Ispizua; Pere Barba; Mi Kwon; Dolores Caballero; Pierre Sesques; Emmanuel Bachy; Roberta Di Blasi; Catherine Thieblemont; Friso Calkoen; Pim G.N.J. Mutsaers; Johan Maertens; Livia Giannoni; Emma Nicholson; Matthew Collin; Carlos Pinho Vaz; Elisabetta Metafuni; Joaquin Martinez-Lopez; Fiona L Dignan; Josep-Maria Ribera; Arnon Nagler; František Folber; Robin Sanderson; Adrian Bloor; Fabio Ciceri; Nina Knelange; Francis Ayuk; Nicolaus Kröger; Marie José Kersten; Stephan Mielke;
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Càncer hematològic; Malalties infeccioses Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Cáncer hematológico; Enfermedades infecciosas Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer; Infectious diseases COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients. For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to severe morbidity and high mortality as compared to the general population [1–3]. For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still limited to small case series and case reports [4–8]. CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present the clinical course of COVID-19 in the largest European cohort to date.
Thomas Chatzikonstantinou; Anargyros Kapetanakis; Lydia Scarfò; Georgios Karakatsoulis; David Allsup; Alejandro Alonso Cabrero; Martin Andres; Darko Antic; Mónica Baile; Panagiotis Baliakas; Dominique Bron; Antonella Capasso; Sofia Chatzileontiadou; Raul Cordoba; Juan-Gonzalo Correa; Carolina Cuéllar-García; Lorenzo De Paoli; Maria Rosaria De Paolis; Giovanni Del Poeta; Christos Demosthenous; Maria Dimou; David Donaldson; Michael Doubek; Maria Efstathopoulou; Barbara Eichhorst; Shaimaa El-Ashwah; Alicia Enrico; Blanca Espinet; Lucia Farina; Angela Ferrari; Myriam Foglietta; Henrik Frederiksen; Moritz Fürstenau; José A. García-Marco; Rocío García-Serra; Massimo Gentile; Eva Gimeno; Andreas Glenthøj; Maria Gomes da Silva; Odit Gutwein; Yervand K Hakobyan; Yair Herishanu; Jose Angel Hernandez-Rivas; Tobias Herold; Idanna Innocenti; Gilad Itchaki; Ozren Jakšić; Ann Janssens; Оlga B Kalashnikova; Elżbieta Kalicińska; Linda Katharina Karlsson; Arnon P. Kater; Sabina Kersting; Jorge Labrador; Deepesh Lad; Luca Laurenti; Mark-David Levin; Enrico Lista; Alberto Lopez-Garcia; Lara Malerba; Roberto Marasca; Monia Marchetti; Juan Marquet; Mattias Mattsson; Francesca Romana Mauro; Ivana Milosevic; Fatima Miras; Marta Morawska; Marina Motta; Talha Munir; Roberta Murru; Carsten Utoft Niemann; Raquel Nunes Rodrigues; Jacopo Olivieri; Lorella Orsucci; Maria Papaioannou; Miguel Arturo Pavlovsky; Inga Piskunova; Viola Maria Popov; Francesca Maria Quaglia; Giulia Quaresmini; Kristian Qvist; Gianluigi Reda; Gian Matteo Rigolin; Rosa Ruchlemer; Gevorg Saghumyan; Amit Shrestha; Martin Simkovic; Martin Spacek; Paolo Sportoletti; Oana Stanca; Niki Stavroyianni; Tamar Tadmor; Doreen te Raa; Sanne H. Tonino; Livio Trentin; Ellen van der Spek; Michel van Gelder; Roel van Kampen; Marzia Varettoni; Andrea Visentin; Candida Vitale; Ewa Wasik-Szczepanek; Tomasz Wróbel; Lucrecia Yáñez San Segundo; Mohamed A. Yassin; Marta Coscia; Alessandro Rambaldi; Emili Montserrat; Robin Foà; Antonio Cuneo; Kostas Stamatopoulos; Paolo Ghia;
Chronic lymphocytic leukemia; Coronavirus infections; Mortality Leucemia linfocítica crónica; Infecciones por coronavirus; Mortalidad Leucèmia limfocítica crònica; Infeccions per coronavirus; Mortalitat Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
James Glasbey; Adesoji Ademuyiwa; Adewale Adisa; Ehab AlAmeer; Alexis P Arnaud; Faris Ayasra; José Azevedo; Ana Minaya-Bravo; Ainhoa Costas-Chavarri; John Edwards; Muhammed Elhadi; Marco Fiore; Christina Fotopoulou; Gaetano Gallo; Dhruva Ghosh; Ewen A Griffiths; Ewen Harrison; Peter Hutchinson; Ismail Lawani; Samuel Lawday; Hans Lederhuber; Sezai Leventoglu; Elizabeth Li; Gustavo Mendonça Ataíde Gomes; Harvinder Mann; Ella J Marson; Janet Martin; Dennis Mazingi; Kenneth McLean; Maria Modolo; Rachel Moore; Dion Morton; Faustin Ntirenganya; Francesco Pata; Maria Picciochi; Peter Pockney; Antonio Ramos-De la Medina; Keith Roberts; April Camilla Roslani; Rajkumar Kottayasamy Seenivasagam; Richard Shaw; Joana Filipa Ferreira Simões; Neil Smart; Grant D Stewart; Richard Sullivan; Sudha Sundar; Stephen Tabiri; Elliott H Taylor; Raghavan Vidya; Dmitri Nepogodiev; Aneel Bhangu; James C Glasbey; Kenneth McLean; Dmitri Nepogodiev; Ewen Harrison; Aneel A Bhangu; Dmitri Nepogodiev; Kwabena Siaw-Acheampong; Ruth A Benson; Edward Bywater; Daoud Chaudhry; Brett E Dawson; Jonathan P Evans; James C Glasbey; Rohan R Gujjuri; Emily Heritage; Conor S Jones; Sivesh K Kamarajah; Chetan Khatri; Rachel A Khaw; James M Keatley; Andrew Knight; Samuel Lawday; Elizabeth Li; Harvinder S Mann; Ella J Marson; Kenneth A McLean; Siobhan C Mckay; Emily C Mills; Gianluca Pellino; Maria Picciochi; Elliott H Taylor; Abhinav Tiwari; Joana FF Simoes; Isobel M Trout; Mary L Venn; Richard JW Wilkin; Aneel Bhangu; James C Glasbey; Neil J Smart; Ana Minaya-Bravo; Jonathan P Evans; Gaetano Gallo; Susan Moug; Francesco Pata; Peter Pockney; Salomone Di Saverio; Abigail Vallance; Dale Vimalchandran; Ewen A Griffiths; Sivesh K Kamarajah; Richard PT Evans; Philip Townend; Keith Roberts; Siobhan McKay; John Isaac; Sohei Satoi; John Edwards; Aman S Coonar; Adrian Marchbank; Edward J Caruana; Georgia R Layton; Akshay Patel; Alessandro Brunelli; Samuel Ford; Anant Desai; Alessandro Gronchi; Marco Fiore; Max Almond; Fabio Tirotta; Sinziana Dumitra; Angelos Kolias; Stephen J Price; Daniel M Fountain; Michael D Jenkinson; Peter Hutchinson; Hani J Marcus; Rory J Piper; Laura Lippa; Franco Servadei; Ignatius Esene; Christian Freyschlag; Iuri Neville; Gail Rosseau; Karl Schaller; Andreas K Demetriades; Faith Robertson; Alex Alamri; Richard Shaw; Andrew G Schache; Stuart C Winter; Michael Ho; Paul Nankivell; Juan Rey Biel; Martin Batstone; Ian Ganly; Raghavan Vidya; Alex Wilkins; Jagdeep K Singh; Dinesh Thekinkattil; Sudha Sundar; Christina Fotopoulou; Elaine YL Leung; Tabassum Khan; Luis Chiva; Jalid Sehouli; Anna Fagotti; Paul Cohen; Murat Gutelkin; Rahel Ghebre; Thomas Konney; Rene Pareja; Rob Bristow; Sean Dowdy; TS Shylasree; Rajkumar Kottayasamy Seenivasagam; Joe Ng; Keiichi Fujiwara; Grant D Stewart; Benjamin Lamb; Krishna Narahari; Alan McNeill; Alexandra Colquhoun; John S McGrath; Steve Bromage; Ravi Barod; Veeru Kasivisvanathan; Tobias Klatte; Joana FF Simoes; Tom EF Abbott; Sadi Abukhalaf; Michel Adamina; Adesoji O Ademuyiwa; Arnav Agarwal; Murat Akkulak; Ehab Alameer; Derek Alderson; Felix Alakaloko; Markus Albertsmeier; Osaid Alser; Muhammad Alshaar; Sattar Alshryda; Alexis P Arnaud; Knut Magne Augestad; Faris Ayasra; José Azevedo; Brittany K Bankhead-Kendall; Emma Barlow; David Beard; Ruth A Benson; Joshua Burke; Daniel Cox; Tatiana Garmanova; Andrey Litvin; Markus W Löffler; Thomas D Pinkney; Dejan Radenkovic; Martin Rutegård; Juan José Segura-Sampedro; Andrew Schache; Malin Sund; Gabrielle H van Ramshorst; Oliver J Warren;
En este estudio internacional, prospectivo y de cohortes, participaron 20 006 pacientes adultos (≥18 años) de 466 hospitales de 61 países con 15 tipos de cáncer, que tuvieron una decisión de cirugía curativa durante la pandemia de COVID-19 y fueron seguidos hasta el momento de la cirugía o del cese del seguimiento (31 de agosto de 2020). Se calcularon las puntuaciones medias nacionales de Oxford COVID-19 Se calcularon las puntuaciones medias nacionales del Índice de Estrictez de Oxford para definir la respuesta gubernamental a la COVID-19 para cada paciente durante el de cada paciente durante el periodo de espera de la cirugía, y se clasificaron en restricciones leves (índice 60). (20-60) y restricciones totales (>60). El resultado primario fue la tasa de no operación (definida como la proporción de pacientes que no se sometieron a la cirugía prevista). Se utilizaron modelos de regresión de riesgos proporcionales de Cox para explorar las asociaciones entre entre los bloqueos y la no intervención quirúrgica. Los intervalos entre el diagnóstico y la cirugía se compararon entre los grupos del índice de respuesta del gobierno COVID-19 grupos de índice de respuesta. Este estudio se registró en ClinicalTrials.gov, NCT04384926. This international, prospective, cohort study enrolled 20 006 adult (≥18 years) patients from 466 hospitals in 61 countries with 15 cancer types, who had a decision for curative surgery during the COVID-19 pandemic and were followed up until the point of surgery or cessation of follow-up (Aug 31, 2020). Average national Oxford COVID-19 Stringency Index scores were calculated to define the government response to COVID-19 for each patient for the period they awaited surgery, and classified into light restrictions (index 60). The primary outcome was the non-operation rate (defined as the proportion of patients who did not undergo planned surgery). Cox proportional-hazards regression models were used to explore the associations between lockdowns and non-operation. Intervals from diagnosis to surgery were compared across COVID-19 government response index groups. This study was registered at ClinicalTrials.gov, NCT04384926.